Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dose Group 3 Clear all
Completed Phase 2 Interventional Results available

Study of Milk Allergy and Tolerance in Children

NCT00778258
View directory record Official record
Conditions
Food Hypersensitivity, Milk Hypersensitivity
Interventions
Baked Milk, Non-baked Milk
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 10 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Sep 19, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone

NCT05582707
View directory record Official record
Conditions
Intracerebral Haemorrhage, Intraventricular
Interventions
Pioglitazone 15mg
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

NCT00384787
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP, VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 1 Interventional

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

NCT03386526
View directory record Official record
Conditions
Advanced Solid Tumors or Hematologic Malignancies
Interventions
APG-1387 for Injection
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Ann Arbor, Michigan • Grand Rapids, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Sep 19, 2026, 10:37 PM EDT
Not listed No phase listed Observational

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

NCT05014555
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
GI Alliance
Other
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Jacksonville, Florida • Baton Rouge, Louisiana • Southlake, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

NCT02412111
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Tezacaftor/Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

NCT02760264
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Vamorolone 0.25 mg/kg/day, Vamorolone 0.75 mg/kg/day, Vamorolone 2.0 mg/kg/day, Vamorolone 6.0 mg/kg/day
Drug
Lead sponsor
ReveraGen BioPharma, Inc.
Industry
Eligibility
4 Years to 6 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Davis, California • Gainesville, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2019 · Synced Sep 19, 2026, 10:37 PM EDT
Not listed Phase 4 Interventional

Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair

NCT04573504
View directory record Official record
Conditions
Vaginal Laceration During Delivery
Interventions
Augmentin/Flagyl or Augmentin/Clindamycin, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 1 Interventional

Study of NK012 in Patients With Refractory Solid Tumors

NCT00542958
View directory record Official record
Conditions
Cancer
Interventions
NK012
Drug
Lead sponsor
Nippon Kayaku Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults

NCT02666963
View directory record Official record
Conditions
Healthy
Interventions
RTA 901 Capsules, 10 or 40 mg, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency

NCT01700387
View directory record Official record
Conditions
Chronic Migraine
Interventions
onabotulinumtoxinA, Topiramate, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

NCT02620787
View directory record Official record
Conditions
Diabetes, Wound Infection, Healthy Volunteers
Interventions
Tedizolid, Microdialysis Catheter Insertion
Drug · Procedure
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 19, 2026, 10:37 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

NCT05094336
View directory record Official record
Conditions
Advanced MTAP-null Solid Tumors
Interventions
Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Oxnard, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines

NCT05973006
View directory record Official record
Conditions
COVID-19
Interventions
NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
Biological
Lead sponsor
Novavax
Industry
Eligibility
11 Years to 18 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
20
States / cities
Davie, Florida • Jacksonville, Florida • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 19, 2026, 10:37 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

ITT-5 Mechanisms of Spermatogenesis in Man

NCT02147964
View directory record Official record
Conditions
Gonadotropin Deficiency
Interventions
Testosterone 1% Gel, Acyline, Dutasteride, Ketoconazole, HCG, placebo dutasteride, placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 19, 2026, 10:37 PM EDT
Terminated Early Phase 1 Interventional

Gene Transfer for HIV Using Autologous T Cells

NCT01153646
View directory record Official record
Conditions
HIV-1 Infection
Interventions
pHIV7-shI-TAR-CCR5RZ treated CD4 cells
Genetic
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2011 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06683508
View directory record Official record
Conditions
Obesity, Overweight
Interventions
LY3549492, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
49
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 19, 2026, 10:37 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

NCT07075640
View directory record Official record
Conditions
Healthy Participants
Interventions
AG-236, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers

NCT06188325
View directory record Official record
Conditions
Gaucher's Disease
Interventions
Eliglustat
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Results available

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT01390818
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer, Melanoma, Colorectal Cancer
Interventions
MSC1936369B (pimasertib), SAR245409 (PI3K and mTOR inhibitor)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 82 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 19, 2026, 10:37 PM EDT
Active, not recruiting Not applicable Interventional

Interventions for English Language Learners At-Risk for ADHD

NCT05918991
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Daily Report Card, Language Intervention
Behavioral · Other
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

NCT00768690
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-333, ketoconazole, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

NCT01645280
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 19, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants

NCT00674648
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
CMV-Peptide-Specific T cells
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 19, 2026, 10:37 PM EDT